AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
+0.52%Aug 13, 2026, 01:27 UTC
Atea Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.
Source:Aug 12, 2026, 20:05 UTC
Atea Pharmaceuticals reported that its Phase 3 C-BEYOND trial of BEM/RZR for hepatitis C met primary and secondary endpoints, supporting a potential best-in-class profile.
Source:Jul 28, 2026, 11:00 UTC
Atea Pharmaceuticals announced that its Bemnifosbuvir/Ruzasvir met primary and secondary endpoints in the Phase 3 C-BEYOND North America trial for hepatitis C virus treatment.
Jul 14, 2026, 11:00 UTC
Atea Pharmaceuticals initiated a first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus.
Source:Jun 25, 2026, 11:00 UTC
Atea Pharmaceuticals completed patient enrollment in its Phase 3 C-FORWARD trial evaluating bemnifosbuvir and ruzasvir for hepatitis C virus treatment.